Aim:
This double-blind (secondary assessor- and analyst-blinded) RCT was designed to evaluate the effects of oral NAC on the treatment of hospitalized patients with COVID-19.
Although it seems that NAC confers significant benefits in patients with mild COVID-19 before hospitalization, the present study focused solely on inpatients. The current study is one of the well-designed RCTs to evaluate the efficacy and safety of NAC as adjuvant therapy in hospitalized patients with COVID-19.